245 related articles for article (PubMed ID: 33108988)
21. [Infusion of Daratumumab in Combination Therapies - Practical Information for The Outpatient Area].
Scheid C; Munder M; Salwender H; Engelhardt M
Dtsch Med Wochenschr; 2018 Aug; 143(16):1201-1206. PubMed ID: 29874684
[TBL] [Abstract][Full Text] [Related]
22. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
Liu J; He HY; Li L; Lu J; Qiang WT; Guo P; Hou N; Jiang H; Du J; Fu WJ
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):27-32. PubMed ID: 33677865
[No Abstract] [Full Text] [Related]
23. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
[TBL] [Abstract][Full Text] [Related]
24. Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.
Nooka AK; Gleason C; Sargeant MO; Walker M; Watson M; Panjic EH; Lonial S
J Oncol Pract; 2018 Jul; 14(7):414-422. PubMed ID: 29996069
[TBL] [Abstract][Full Text] [Related]
25. Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T; Gatt M; Lavie N; Vaxman I; Tadmor T; Rouvio O; Zektser M; Horowitz N; Magen H; Ballan M; Suru C; Luttwak E; Levi S; Ziv-Baran T; Avivi I; Cohen YC
Eur J Haematol; 2021 Feb; 106(2):184-195. PubMed ID: 33090552
[TBL] [Abstract][Full Text] [Related]
26. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
Moreau P; van de Donk NW; San Miguel J; Lokhorst H; Nahi H; Ben-Yehuda D; Cavo M; Cook G; Delforge M; Einsele H; Zweegman S; Ludwig H; Driessen C; Palumbo A; Facon T; Plesner T; Dimopoulos M; Sondergeld P; Sonneveld P; Mateos MV
Drugs; 2016 May; 76(8):853-67. PubMed ID: 27113582
[TBL] [Abstract][Full Text] [Related]
27. Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience.
Byun JM; Yoon SS; Koh Y; Kim I; Jo J; Park H; Lee JO; Lee J
Anticancer Res; 2019 Sep; 39(9):5165-5170. PubMed ID: 31519629
[TBL] [Abstract][Full Text] [Related]
28. Safety and feasibility analysis of rapid daratumumab infusion in Chinese patients with multiple myeloma.
Yin XX; Hu Y; Yang Y; Zhang X; Liu L; Cao X; Chen J; Xia Z; Wang Y
Cancer Med; 2024 Jun; 13(11):e7347. PubMed ID: 38845476
[TBL] [Abstract][Full Text] [Related]
29. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Usmani SZ; Nahi H; Plesner T; Weiss BM; Bahlis NJ; Belch A; Voorhees PM; Laubach JP; van de Donk NWCJ; Ahmadi T; Uhlar CM; Wang J; Feng H; Qi M; Richardson PG; Lonial S
Lancet Haematol; 2020 Jun; 7(6):e447-e455. PubMed ID: 32470437
[TBL] [Abstract][Full Text] [Related]
30. Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses.
Arnall JR; Moore DC; Hill HL; Griffin S; Mueller MK; Lavery LA; Voorhees PM; Usmani SZ
Leuk Lymphoma; 2019 Sep; 60(9):2295-2298. PubMed ID: 30848971
[No Abstract] [Full Text] [Related]
31. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
32. Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Blair HA
Drugs; 2017 Dec; 77(18):2013-2024. PubMed ID: 29127588
[TBL] [Abstract][Full Text] [Related]
33. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
Iida S; Ishikawa T; Min CK; Kim K; Yeh SP; Usmani SZ; Mateos MV; Nahi H; Heuck C; Qin X; Parasrampuria DA; Gries KS; Qi M; Bahlis N; Ito S
Ann Hematol; 2021 Apr; 100(4):1065-1077. PubMed ID: 33599794
[TBL] [Abstract][Full Text] [Related]
34. Infectious and immunological sequelae of daratumumab in multiple myeloma.
Johnsrud AJ; Johnsrud JJ; Susanibar SA; Kamimoto JJ; Kothari A; Burgess M; Van Rhee F; Rico JC
Br J Haematol; 2019 Apr; 185(1):187-189. PubMed ID: 29974956
[No Abstract] [Full Text] [Related]
35. Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.
Chehab S; Panjic EH; Gleason C; Lonial S; Nooka AK
Future Oncol; 2018 Dec; 14(30):3111-3121. PubMed ID: 30136602
[TBL] [Abstract][Full Text] [Related]
36. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
[TBL] [Abstract][Full Text] [Related]
37. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Kaplan P; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Chiu C; Wang J; Carson R; Crist W; Deraedt W; Nguyen H; Qi M; San-Miguel J;
N Engl J Med; 2018 Feb; 378(6):518-528. PubMed ID: 29231133
[TBL] [Abstract][Full Text] [Related]
38. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
Jia YJ; Liu H; Wang LR; Wang T; Feng R; Chen YJ; Wang M; Guo HX; Wen L; Duan WB; Yang YZ; Wang FR; Chen YY; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):347-352. PubMed ID: 32370462
[No Abstract] [Full Text] [Related]
39. Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab.
Moore DC; Arnall JR; Thompson DL; Martin AL; Robinson J; Ndiaye A; Paul B; Atrash S; Bhutani M; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e777-e781. PubMed ID: 32660902
[TBL] [Abstract][Full Text] [Related]
40. Daratumumab for the treatment of multiple myeloma.
Touzeau C; Moreau P
Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]